ReviewFrontiers in medicine2026

Glucagon-like peptide-1 and dual/triple receptor agonists in the treatment of metabolic dysfunction-associated steatotic liver disease: advances in mechanistic research.

Xinyi Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.